15 / 22
1er RETO: ¿Es esta indicación sostenible? RESPONSABILIDAD SOCIAL
CONCLUSION - UK:
While nivolumab improves overall survival, at its current
cost it would not be
considered a cost-effective
treatment option for patients with HNC.
CONCLUSION - USA:
Nivolumab is preferred to single-agent cetuximab
but requires a
willingness-to-pay of at least $150,000/QALY to be considered cost-
effective
when compared to docetaxel or methotrexate. Selection by
PD-L1 does not markedly improve the cost-effectiveness of nivolumab.
This informs patient selection and clinical care-path development.
CONCLUCION – CANADA:
We conclude that although nivolumab offers clinical benefit for the treatment of
r/m HNSCC over current regimens,
it is not cost-effective
based on its list price.
Nivolumab would be cost-effective if its price was reduced by 20%. Our
subgroup analysis seemed to indicate that nivolumab might be cost-effective for
tumors with expression of PDL-1 >5%.
Selección
pacientes
F. Clínicos
BMK